Tuesday, 28 July 2009

Malathion 0.5% topical Lotion (Ovider): Innovator Taro Sued generic players in a bid to block generic version

Innovator Taro Pharmaceutical Industries (announced in a press release Here ) that it has filed a patent infringement lawsuit against generic players Synerx Pharma, DPT Labs and Karalex Pharma in the United States District Court for New Jersey for infringement of following Orange Book listed patent:


US7560445 (Assignee: Taro Pharma; Expiry: Feb 1, 2027): The patent covers a topical pharmaceutical composition comprising malathion, said malathion having a purity of greater than about 98.5%


Malathion 0.5% topical Lotion (Ovider) is used for the treatment of patients infected with pediculus humanus capitis (head lice and their ova) of the scalp hair

1 comment:

Unknown said...

Malathion Registration Review Docket; Reopening of Comment Period until October 5th, 2009

EPA issued a notice in the Federal Register of June 24, 2009, concerning the availability of multiple registration review dockets for public comment, including malathion. This document reopens the comment period for the malathion registration review docket, which closed on August 24, 2009, until October 5, 2009.

DATES: Comments, identified by docket identification (ID) number EPA-HQ-OPP-2009-0317, must be received on or before October 5, 2009.

FOR FURTHER INFORMATION CONTACT: Eric Miederhoff, Special Review and Reregistration Division (7508P), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460-0001; telephone number: (703) 347-8028; e-mail address: miederhoff.eric@epa.gov.

Malathion information was found at http://www.CyberRegs.com

web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker